Shoda Lisl K M, Young Daniel L, Ramanujan Saroja, Whiting Chan C, Atkinson Mark A, Bluestone Jeffrey A, Eisenbarth George S, Mathis Diane, Rossini Aldo A, Campbell Scott E, Kahn Richard, Kreuwel Huub T C
Entelos Inc., Foster City, California 94404, USA.
Immunity. 2005 Aug;23(2):115-26. doi: 10.1016/j.immuni.2005.08.002.
Type 1 diabetes (T1D) animal models such as the nonobese diabetic (NOD) mouse have improved our understanding of disease pathophysiology, but many candidate therapeutics identified therein have failed to prevent/cure human disease. We have performed a comprehensive evaluation of disease-modifying agents tested in the NOD mouse based on treatment timing, duration, study length, and efficacy. Interestingly, some popular tenets regarding NOD interventions were not confirmed: all treatments do not prevent disease, treatment dose and timing strongly influence efficacy, and several therapies have successfully treated overtly diabetic mice. The analysis provides a unique perspective on NOD interventions and suggests that the response of this model to therapeutic interventions can be a useful predictor of the human response as long as careful consideration is given to treatment dose, timing, and protocols; more thorough investigation of these parameters should improve clinical translation.
1型糖尿病(T1D)动物模型,如非肥胖糖尿病(NOD)小鼠,增进了我们对疾病病理生理学的理解,但其中确定的许多候选治疗方法未能预防/治愈人类疾病。我们基于治疗时间、持续时间、研究时长和疗效,对在NOD小鼠中测试的疾病改善剂进行了全面评估。有趣的是,一些关于NOD干预的流行观点未得到证实:并非所有治疗都能预防疾病,治疗剂量和时间对疗效有强烈影响,并且几种疗法已成功治疗明显糖尿病小鼠。该分析为NOD干预提供了独特视角,并表明只要仔细考虑治疗剂量、时间和方案,该模型对治疗干预的反应就可以成为人类反应的有用预测指标;对这些参数进行更深入的研究应能改善临床转化。